<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Surgical Oncology &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/surgical-oncology/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 18 Jan 2026 17:15:56 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Surgical Oncology &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Preoperative Interleukin 2: Impact on Cancer Surgery Outcomes</title>
		<link>https://bioengineer.org/preoperative-interleukin-2-impact-on-cancer-surgery-outcomes/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 18 Jan 2026 17:15:35 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[ameliyat öncesi dönemde (preoperatif)]]></category>
		<category><![CDATA[Cancer Immunomodulation** **Açıklama:** 1. **Preoperative Immunotherapy:** Makalenin temel odağı]]></category>
		<category><![CDATA[Cancer surgery outcomes]]></category>
		<category><![CDATA[en uygun 5 etiket: **Preoperative Immunotherapy]]></category>
		<category><![CDATA[Gastrointestinal cancer]]></category>
		<category><![CDATA[Gastrointestinal Cancer Surgery]]></category>
		<category><![CDATA[Interleukin 2]]></category>
		<category><![CDATA[Interleukin 2 Therapy]]></category>
		<category><![CDATA[Makale içeriği ve anahtar kelimeler göz önüne alındığında]]></category>
		<category><![CDATA[Meta-analysis]]></category>
		<category><![CDATA[Preoperative immunotherapy]]></category>
		<category><![CDATA[Surgical Oncology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/preoperative-interleukin-2-impact-on-cancer-surgery-outcomes/</guid>

					<description><![CDATA[Recent advancements in immunotherapy have generated considerable interest within the scientific community, particularly in the context of cancer treatment. One emergent focal point of this research is the role of recombinant Interleukin 2 (rIL-2) in preoperative immunomodulation, especially for patients undergoing gastrointestinal cancer surgery. A systematic review and meta-analysis led by Horcicka et al. aims [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">317989</post-id>	</item>
		<item>
		<title>Targeted Intraoperative Radiotherapy Advances in Early Breast Cancer</title>
		<link>https://bioengineer.org/targeted-intraoperative-radiotherapy-advances-in-early-breast-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 10 Sep 2025 05:51:14 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[early breast cancer treatment]]></category>
		<category><![CDATA[patient-centered care]]></category>
		<category><![CDATA[radiation therapy innovation]]></category>
		<category><![CDATA[Surgical Oncology]]></category>
		<category><![CDATA[Targeted intraoperative radiotherapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/targeted-intraoperative-radiotherapy-advances-in-early-breast-cancer/</guid>

					<description><![CDATA[In recent years, the landscape of breast cancer treatment has undergone a notable transformation, particularly with the introduction of targeted intraoperative radiotherapy (TARGIT). This technique aims to deliver precise radiation treatment directly to the tumor site during surgery, thereby minimizing exposure to surrounding healthy tissues. Researchers led by Das et al. have delved deep into [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">268209</post-id>	</item>
		<item>
		<title>Dr. Jeremy L. Davis Appointed UMGCCC Surgical Oncology Lead and Chief of Surgical Oncology Division at UMSOM</title>
		<link>https://bioengineer.org/dr-jeremy-l-davis-appointed-umgccc-surgical-oncology-lead-and-chief-of-surgical-oncology-division-at-umsom/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 21 Jan 2025 19:51:19 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CDH1 Gene]]></category>
		<category><![CDATA[Hereditary Gastric Cancer]]></category>
		<category><![CDATA[Leadership Appointment]]></category>
		<category><![CDATA[Surgical Oncology]]></category>
		<category><![CDATA[UMGCCC]]></category>
		<guid isPermaLink="false">https://bioengineer.org/dr-jeremy-l-davis-appointed-umgccc-surgical-oncology-lead-and-chief-of-surgical-oncology-division-at-umsom/</guid>

					<description><![CDATA[Groundbreaking Appointment in Surgical Oncology at UMGCCC: Jeremy L. Davis, MD, Takes the Helm as New Surgical Oncology Lead In a significant move for the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), renowned surgical oncologist Dr. Jeremy L. Davis has been appointed as the new Surgical Oncology Lead and Chief of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">234399</post-id>	</item>
	</channel>
</rss>
